S&P 500   3,271.03 (-3.53%)
DOW   26,519.95 (-3.43%)
QQQ   272.44 (-3.62%)
AAPL   111.55 (-4.33%)
MSFT   202.75 (-4.92%)
FB   273.47 (-3.47%)
GOOGL   1,525.58 (-4.58%)
AMZN   3,170.21 (-3.53%)
TSLA   405.16 (-4.60%)
NVDA   506.00 (-5.57%)
BABA   307.81 (-2.94%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.34 (-3.12%)
AMD   76.32 (-3.25%)
T   26.51 (-1.52%)
F   8.13 (+2.65%)
ACB   3.83 (-4.25%)
GILD   59.92 (-0.15%)
NFLX   486.00 (-0.60%)
NIO   27.30 (-4.01%)
BA   148.17 (-4.55%)
DIS   118.63 (-3.80%)
S&P 500   3,271.03 (-3.53%)
DOW   26,519.95 (-3.43%)
QQQ   272.44 (-3.62%)
AAPL   111.55 (-4.33%)
MSFT   202.75 (-4.92%)
FB   273.47 (-3.47%)
GOOGL   1,525.58 (-4.58%)
AMZN   3,170.21 (-3.53%)
TSLA   405.16 (-4.60%)
NVDA   506.00 (-5.57%)
BABA   307.81 (-2.94%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.34 (-3.12%)
AMD   76.32 (-3.25%)
T   26.51 (-1.52%)
F   8.13 (+2.65%)
ACB   3.83 (-4.25%)
GILD   59.92 (-0.15%)
NFLX   486.00 (-0.60%)
NIO   27.30 (-4.01%)
BA   148.17 (-4.55%)
DIS   118.63 (-3.80%)
S&P 500   3,271.03 (-3.53%)
DOW   26,519.95 (-3.43%)
QQQ   272.44 (-3.62%)
AAPL   111.55 (-4.33%)
MSFT   202.75 (-4.92%)
FB   273.47 (-3.47%)
GOOGL   1,525.58 (-4.58%)
AMZN   3,170.21 (-3.53%)
TSLA   405.16 (-4.60%)
NVDA   506.00 (-5.57%)
BABA   307.81 (-2.94%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.34 (-3.12%)
AMD   76.32 (-3.25%)
T   26.51 (-1.52%)
F   8.13 (+2.65%)
ACB   3.83 (-4.25%)
GILD   59.92 (-0.15%)
NFLX   486.00 (-0.60%)
NIO   27.30 (-4.01%)
BA   148.17 (-4.55%)
DIS   118.63 (-3.80%)
S&P 500   3,271.03 (-3.53%)
DOW   26,519.95 (-3.43%)
QQQ   272.44 (-3.62%)
AAPL   111.55 (-4.33%)
MSFT   202.75 (-4.92%)
FB   273.47 (-3.47%)
GOOGL   1,525.58 (-4.58%)
AMZN   3,170.21 (-3.53%)
TSLA   405.16 (-4.60%)
NVDA   506.00 (-5.57%)
BABA   307.81 (-2.94%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.34 (-3.12%)
AMD   76.32 (-3.25%)
T   26.51 (-1.52%)
F   8.13 (+2.65%)
ACB   3.83 (-4.25%)
GILD   59.92 (-0.15%)
NFLX   486.00 (-0.60%)
NIO   27.30 (-4.01%)
BA   148.17 (-4.55%)
DIS   118.63 (-3.80%)
Log in
NASDAQ:SYRS

Syros Pharmaceuticals Stock Forecast, Price & News

$6.66
-0.34 (-4.86 %)
(As of 10/28/2020 03:59 PM ET)
Add
Compare
Today's Range
$6.52
Now: $6.66▼
$7.05
50-Day Range
$6.83
MA: $8.95▼
$10.40
52-Week Range
$4.26
Now: $6.66▼
$14.69
Volume15,240 shs
Average Volume344,962 shs
Market Capitalization$304.77 million
P/E RatioN/A
Dividend YieldN/A
Beta1.85
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Read More
Syros Pharmaceuticals logo

Beat the Market (BTM) Rank™

Analyst Opinion: 4.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.60 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYRS
Previous Symbol
CUSIPN/A
CIK1556263
Webwww.syros.com
Phone617-744-1340
Employees83

Debt

Debt-to-Equity Ratio0.32
Current Ratio4.85
Quick Ratio4.85

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.98 million
Price / Sales153.93
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.87 per share
Price / Book3.56

Profitability

EPS (Most Recent Fiscal Year)($1.88)
Net Income$-75,440,000.00
Net Margins-1,114.79%
Return on Equity-94.59%
Return on Assets-49.05%

Miscellaneous

Outstanding Shares45,762,000
Market Cap$304.77 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$6.66
-0.34 (-4.86 %)
(As of 10/28/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SYRS News and Ratings via Email

Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

How has Syros Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SYRS stock has increased by 30.7% and is now trading at $6.73.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Syros Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Syros Pharmaceuticals.

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Syros Pharmaceuticals.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) issued its earnings results on Thursday, August, 6th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.02. The company earned $3.19 million during the quarter, compared to analysts' expectations of $2.19 million. Syros Pharmaceuticals had a negative return on equity of 94.59% and a negative net margin of 1,114.79%.
View Syros Pharmaceuticals' earnings history.

What price target have analysts set for SYRS?

8 brokers have issued 1-year target prices for Syros Pharmaceuticals' shares. Their forecasts range from $9.00 to $20.00. On average, they anticipate Syros Pharmaceuticals' stock price to reach $15.57 in the next year. This suggests a possible upside of 131.4% from the stock's current price.
View analysts' price targets for Syros Pharmaceuticals.

Are investors shorting Syros Pharmaceuticals?

Syros Pharmaceuticals saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 5,610,000 shares, an increase of 15.7% from the September 30th total of 4,850,000 shares. Based on an average daily trading volume, of 417,000 shares, the days-to-cover ratio is presently 13.5 days. Currently, 14.2% of the company's shares are sold short.
View Syros Pharmaceuticals' Short Interest.

Who are some of Syros Pharmaceuticals' key competitors?

Some companies that are related to Syros Pharmaceuticals include Mersana Therapeutics (MRSN), Endo International (ENDP), Kiniksa Pharmaceuticals (KNSA), Trillium Therapeutics (TRIL), Karyopharm Therapeutics (KPTI), NGM Biopharmaceuticals (NGM), Keros Therapeutics (KROS), MacroGenics (MGNX), Cytokinetics (CYTK), Zogenix (ZGNX), Applied Molecular Transport (AMTI), Phathom Pharmaceuticals (PHAT), Retrophin (RTRX), Constellation Pharmaceuticals (CNST) and BioXcel Therapeutics (BTAI).
View all competitors.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the following people:
  • Dr. Nancy A. Simonian, Pres, CEO & Director (Age 59, Pay $897.05k)
  • Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 66, Pay $165k)
  • Dr. Eric R. Olson, Chief Scientific Officer (Age 62, Pay $638.63k)
  • Dr. David A. Roth, Chief Medical Officer (Age 57, Pay $641.48k)
  • Dr. Nathanael S. Gray Ph.D., Scientific Founder & Member of Scientific Advisory Board

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $6.73.

How big of a company is Syros Pharmaceuticals?

Syros Pharmaceuticals has a market capitalization of $307.98 million and generates $1.98 million in revenue each year. The company earns $-75,440,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. Syros Pharmaceuticals employs 83 workers across the globe.

What is Syros Pharmaceuticals' official website?

The official website for Syros Pharmaceuticals is www.syros.com.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]

This page was last updated on 10/28/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.